UW Medicine’s lung care and lung transplantation services, located at Harborview and UW Medical Center in Seattle, combine pulmonary and critical care medicine, thoracic surgery and lung transplantation to provide the highest quality patient care for the entire spectrum of pulmonary and critical care illnesses.
UW Medicine’s lung care service is comprised of a multidisciplinary team of specialists dedicated to providing expert care for pulmonary and critical care illnesses requiring medical or surgical treatments with emphasis on asthma
; emphysema and chronic obstructive pulmonary disease, or COPD
; chronic bronchitis; acute lung injury, including acute respiratory distress syndrome, or ARDS; cystic fibrosis
; pulmonary fibrosis
; neuromuscular disorders, such as amyotrophic lateral sclerosis, or ALS, and muscular dystrophy; pulmonary hypertension; pulmonary complications of AIDS; sleep disorders
; pulmonary rehabilitation
; pulmonary thromboendarterectomy; lung cancer
; lung volume reduction surgery; lung transplantation surgery
and minimally invasive thoracic surgery, such as video-assisted thoracscopic surgery, or VATS
UW Medical Center has the only active lung transplantation program in the Pacific Northwest, serving patients in Washington, Alaska, Montana, Idaho and Oregon. In 2017, our surgeons performed the 900th lung transplant.
Harborview’s pulmonary and critical care medicine team is a world leader in improving treatment of the acute respiratory distress syndrome (ARDS). Each year in the United States, 200,000 people suffer acute lung injury. The condition is associated with 75,000 deaths and 3.6 million hospital days. Thanks to the medical discovery and patient care at Harborview, patients with ARDS now have much better chances of surviving.
UW Medicine has one of the world’s leading experts in interstitial lung disease. The UW School of Medicine participates in the National Institutes of Health-sponsored IPFnet, a network of 22 medical centers across the United States that excels in the treatment of idiopathic pulmonary fibrosis. The network’s goal is to find effective therapies for patients with both the early and advanced stages of this devastating disease.